VIYASH · NSE
Viyash Scientific Limited
₹249.65
+2.11% (+₹5.15)
Prev. close
₹244.5
Volume
14,18,518
Delivery %
56.9%
As of
18 Sept 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Viyash Scientific for intraday trading, recommending a buy at ₹267 with a target of ₹285 and a stop loss at ₹…” | Vaishali ParekhPrabhudas Lilladher | Viyash Scientific | PENDING |
Fundamentals
About Viyash Scientific Limited
Viyash Scientific Limited operates as a veterinary pharmaceutical Company in India, the United States, Spain, and internationally. The company provides active pharmaceutical ingredients, finished dosage formulations, analytical services, and VET formulation services for cattle and poultry. The company was formerly known as Sequent Scientific Limited and changed its name to Viyash Scientific Limited in January 2026. The company was incorporated in 1985 and is headquartered in Hyderabad, India. Viyash Scientific Limited operates as a subsidiary of CA Harbor Investments.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Hari Babu Bodepudi
Headquarters
Hyderabad
Employees
2,900
Website
viyash.comExchange
View on NSE ↗Key stats
Market cap
₹10,987.30 Cr
P/E ratio (TTM)
52.6
EPS (TTM)
₹4.75
Beta (1Y · daily vs NIFTY 50)
1.39
Beta (5Y · monthly vs NIFTY 50)
1.83
Shares float
20.64 Cr
EPS · quarter ended Jun 2026
₹1.47
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,361.62 Cr | ₹1,412.82 Cr | ₹1,420.91 Cr | ₹1,369.73 Cr | ₹2,963.40 Cr | ₹3,420.31 Cr | |
| EBITDA | ₹211.61 Cr | ₹120.25 Cr | ₹-52.25 Cr | ₹53.32 Cr | ₹331.23 Cr | ₹651.87 Cr |
| ₹95.44 Cr | ₹41.25 Cr | ₹-121.16 Cr | ₹-35.87 Cr | ₹23.22 Cr | ₹177.28 Cr | |
| Diluted EPS | ₹3.85 | ₹1.65 | ₹-4.88 | ₹-1.44 | ₹0.53 | ₹4.01 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹1,529.12 Cr | ₹1,540.38 Cr | ₹4,132.27 Cr | ₹4,628.39 Cr | |
| — | — | ₹443.60 Cr | ₹487.69 Cr | ₹654.30 Cr | ₹489.75 Cr | |
| Stockholders' equity | — | — | ₹698.78 Cr | ₹656.56 Cr | ₹2,431.59 Cr | ₹2,911.06 Cr |
Total assets, Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹114.75 Cr | ₹30.60 Cr | ₹16.81 Cr | ₹30.59 Cr | ₹344.80 Cr | ₹322.91 Cr | |
| Investing cash flow | ₹9.65 Cr | ₹-94.10 Cr | ₹-64.96 Cr | ₹-5.92 Cr | ₹-447.22 Cr | ₹-84.12 Cr |
| ₹-138.75 Cr | ₹67.26 Cr | ₹32.23 Cr | ₹-1.44 Cr | ₹87.04 Cr | ₹-123.33 Cr | |
| Capital expenditure | ₹-52.83 Cr | ₹-32.46 Cr | ₹-86.18 Cr | ₹-30.81 Cr | ₹-108.06 Cr | ₹-134.72 Cr |
| End cash position | ₹53.74 Cr | ₹57.50 Cr | ₹41.57 Cr | ₹64.81 Cr | ₹140.30 Cr | ₹255.76 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22 | Jun 22–Sep 23(6Q) | Dec 23–Mar 24(2Q) | Jun 24 | Sep 24 | Dec 24–Jun 25(3Q) | Sep 25 | Dec 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 53.52% | 53.02% | 53.02% | 52.79% | 52.79% | 52.78% | 52.76% | 52.61% | 52.33% | 61.43% | 61.41% | 61.31% | 61.31% |
| Public | 45.88% | 46.44% | 46.47% | 46.82% | 47.04% | 47.05% | 47.07% | 47.23% | 47.51% | 38.48% | 38.49% | 38.59% | 38.60% |
| Employee trusts | 0.60% | 0.54% | 0.51% | 0.39% | 0.17% | 0.17% | 0.17% | 0.16% | 0.16% | 0.09% | 0.09% | 0.09% | 0.09% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Viyash Scientific Limited | ₹10,987.30 Cr | ₹249.65 | 52.6 | 3.77 | 6.1% | 0.17 | +13.3% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 27
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
8 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.